Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 11 points (0.1%) at 16,218 as of Tuesday, Feb. 25, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,600 issues advancing vs. 1,298 declining with 186 unchanged. The Health Services industry currently sits down 0.4% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include Tenet Healthcare ( THC), down 8.0%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 5.4%, Community Health Systems ( CYH), down 3.9%, ResMed ( RMD), down 2.9% and DaVita HealthCare Partners ( DVA), down 1.5%. A company within the industry that increased today was Agilent Technologies ( A), up 1.2%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. WellPoint ( WLP) is one of the companies pushing the Health Services industry lower today. As of noon trading, WellPoint is down $0.77 (-0.8%) to $90.16 on light volume. Thus far, 865,495 shares of WellPoint exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $89.98-$91.66 after having opened the day at $91.66 as compared to the previous trading day's close of $90.93. WellPoint, Inc., a health benefits company, through its subsidiaries, provides a range of medical and specialty products in the United States. WellPoint has a market cap of $26.2 billion and is part of the health care sector. Shares are down 1.6% year-to-date as of the close of trading on Monday. Currently there are 6 analysts that rate WellPoint a buy, no analysts rate it a sell, and 10 rate it a hold. TheStreet Ratings rates WellPoint as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full WellPoint Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.